ImmuPharma plc (IMMPF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
IMMPF representa a ImmuPharma plc, una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). Calificado con 44/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 18 mar 2026ImmuPharma plc (IMMPF) Resumen de Asistencia Médica y Tuberías
ImmuPharma plc is a biopharmaceutical company specializing in peptide-based therapeutics, with a focus on autoimmunity and inflammation. Its lead candidate, Lupuzor, targeting lupus, is currently in Phase III trials. The company also develops treatments for fungal infections and antibacterial solutions, operating within the competitive biotechnology sector.
Tesis de Inversión
ImmuPharma's investment thesis hinges on the successful completion and commercialization of Lupuzor, their lead drug candidate for lupus, currently in Phase III trials. Positive trial results could drive significant value, given the substantial market for lupus treatments. The company's pipeline of peptide-based therapeutics, including BioAMB and BioCin, offers additional potential revenue streams. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and securing funding for ongoing research and development. With a market capitalization of $0.03 billion and a negative P/E ratio of -6.60, the company's financial performance is closely tied to the success of its clinical programs. Upcoming data releases from the Phase III trial of Lupuzor will be a key catalyst to watch.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.03 billion reflects the company's current valuation in the biotechnology sector.
- Phase III clinical trial for Lupuzor represents a critical milestone with potential for significant market impact.
- Collaboration with Centre National de la Recherche Scientifique expands the company's research capabilities in diabetes therapeutics.
- Negative P/E ratio of -6.60 indicates that the company is currently not profitable, common for development-stage biopharmaceutical companies.
- Beta of 1.41 suggests that the stock is more volatile than the market average.
Competidores y Pares
Fortalezas
- Proprietary peptide-based drug development platform.
- Lead product candidate, Lupuzor, in Phase III clinical trials.
- Focus on unmet medical needs in autoimmunity, inflammation, and anti-infectives.
- Collaboration with Centre National de la Recherche Scientifique.
Debilidades
- Limited financial resources.
- Dependence on the success of Lupuzor.
- Small number of employees.
- OTC market listing.
Catalizadores
- Upcoming: Data releases from the Phase III clinical trial of Lupuzor.
- Upcoming: Potential regulatory submissions for Lupuzor.
- Ongoing: Advancement of BioAMB and BioCin through preclinical and clinical development.
- Ongoing: Securing strategic partnerships and licensing agreements.
- Ongoing: Expansion of diabetes therapeutics pipeline through collaboration with Centre National de la Recherche Scientifique.
Riesgos
- Potential: Failure of Lupuzor Phase III clinical trial.
- Potential: Regulatory rejection of Lupuzor.
- Ongoing: Competition from larger pharmaceutical companies.
- Ongoing: Funding challenges for research and development.
- Ongoing: Risks associated with OTC market listing.
Oportunidades de crecimiento
- Successful completion and commercialization of Lupuzor for lupus treatment: The global lupus therapeutics market is projected to reach billions of dollars. Positive Phase III trial results and subsequent regulatory approval could provide ImmuPharma with a significant revenue stream. Timeline: Anticipated data releases and regulatory submissions within the next 12-24 months.
- Development and commercialization of BioAMB for fungal infections: The market for antifungal drugs is substantial, driven by increasing incidence of invasive fungal infections. BioAMB's peptide-based approach could offer advantages over existing treatments. Timeline: Preclinical and clinical development ongoing, with potential for market entry in 3-5 years.
- Advancement of BioCin as a novel antibacterial drug: With rising antibiotic resistance, there is a critical need for new antibacterial agents. BioCin targets high medical need cases and last-line-of-defense situations. Timeline: Preclinical and clinical development ongoing, with potential for market entry in 5-7 years.
- Expansion of diabetes therapeutics pipeline through collaboration with Centre National de la Recherche Scientifique: The diabetes market is large and growing, driven by increasing prevalence of type 1 and type 2 diabetes. Developing novel peptide-based therapies could provide ImmuPharma with a foothold in this market. Timeline: Ongoing research and development, with potential for clinical candidates in 3-5 years.
- Strategic partnerships and licensing agreements: ImmuPharma can leverage partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline products. Licensing agreements can provide upfront payments and milestone payments, as well as royalties on future sales. Timeline: Ongoing efforts to secure partnerships and licensing agreements.
Oportunidades
- Positive results from Lupuzor Phase III trial.
- Expansion of pipeline through research and development.
- Strategic partnerships and licensing agreements.
- Growing market for autoimmune disease treatments.
Amenazas
- Clinical trial failures.
- Regulatory hurdles.
- Competition from larger pharmaceutical companies.
- Funding challenges.
Ventajas competitivas
- Proprietary peptide-based drug development platform.
- Patent protection for drug candidates.
- Clinical trial data demonstrating safety and efficacy.
- Strategic collaborations with research institutions.
Acerca de IMMPF
Founded in 1999 and headquartered in London, ImmuPharma plc is a biopharmaceutical company dedicated to the discovery and development of peptide-based therapeutics. The company focuses on addressing unmet medical needs in autoimmunity, inflammation, and anti-infectives. Their lead product candidate, Lupuzor, is an autophagy immunomodulator currently in Phase III clinical trials for the treatment of lupus, a chronic autoimmune inflammatory disease affecting millions worldwide. Beyond Lupuzor, ImmuPharma is developing BioAMB, a peptide-based drug targeting Amphotericin-B formulations for fungal infections, and BioCin, a peptide-based antibacterial drug for high medical need cases. ImmuPharma collaborates with Centre National de la Recherche Scientifique for developing a peptide technology platform to treat diabetes, exploring glucagon-like peptide-1 agonists and glucagon antagonists. They also have a license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma's strategy involves identifying and developing novel peptide-based therapies to improve patient outcomes in areas with significant unmet medical needs.
Qué hacen
- Discovers and develops peptide-based therapeutics.
- Focuses on therapies for autoimmunity and inflammation.
- Develops anti-infective drugs.
- Conducts clinical trials to evaluate drug candidates.
- Collaborates with research institutions and pharmaceutical companies.
- Seeks regulatory approvals for its products.
Modelo de Negocio
- Develops and patents peptide-based drug candidates.
- Conducts preclinical and clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA and EMA.
- Commercializes approved drugs directly or through partnerships.
Contexto de la Industria
ImmuPharma operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The autoimmune disease market, particularly for lupus treatments, is a growing area of focus. Competition includes companies developing novel biologics and small molecule drugs. ImmuPharma's peptide-based approach offers a differentiated strategy, but the company faces challenges from larger, more established players with greater resources. The biotechnology industry is driven by innovation, clinical trial outcomes, and regulatory approvals.
Clientes Clave
- Patients suffering from autoimmune diseases like lupus.
- Patients with fungal infections.
- Patients requiring antibacterial treatments.
- Healthcare providers prescribing ImmuPharma's drugs.
Finanzas
Gráfico e información
Precio de la acción de ImmuPharma plc (IMMPF): Price data unavailable
Últimas noticias
-
ImmuPharma raises up to £7.5m to accelerate diabetes drug development
proactiveinvestors.co.uk · 17 mar 2026
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para IMMPF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para IMMPF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de IMMPF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Timothy Paul McCarthy XIV, FCCA, MBA
CEO
Timothy Paul McCarthy XIV is a seasoned executive with FCCA and MBA credentials. His background includes extensive experience in financial management, corporate strategy, and leadership roles within various organizations. He has a proven track record of driving growth and improving operational efficiency. His expertise spans across multiple industries, providing him with a broad perspective on business challenges and opportunities.
Historial: As CEO of ImmuPharma plc, Timothy Paul McCarthy XIV oversees the company's strategic direction and operational execution. He is responsible for guiding the development and commercialization of the company's pipeline products, including Lupuzor. Under his leadership, ImmuPharma has focused on advancing its clinical programs and securing partnerships to support its growth initiatives.
Información del mercado OTC de IMMPF
The OTC Other tier represents the lowest tier of the OTC market, indicating that ImmuPharma plc may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, which increases the risk for investors. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and oversight, resulting in less transparency and potentially higher volatility.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure due to OTC Other tier status.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher volatility compared to stocks listed on major exchanges.
- Increased risk of fraud or mismanagement.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's pipeline and clinical trial data.
- Check for any legal or regulatory issues.
- Monitor trading volume and price fluctuations.
- Consult with a financial advisor.
- Phase III clinical trial for Lupuzor suggests a degree of scientific validation.
- Collaboration with Centre National de la Recherche Scientifique indicates research credibility.
- Development of peptide-based therapeutics addresses unmet medical needs.
- Presence of a CEO with FCCA and MBA credentials.
- Founded in 1999, indicating some operational history.
Acciones de ImmuPharma plc: Preguntas Clave Respondidas
¿Cuáles son los factores clave para evaluar IMMPF?
ImmuPharma plc (IMMPF) actualmente tiene una puntuación IA de 44/100, indicando puntuación baja. Fortaleza clave: Proprietary peptide-based drug development platform.. Riesgo principal a monitorear: Potential: Failure of Lupuzor Phase III clinical trial.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de IMMPF?
IMMPF actualmente puntúa 44/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de IMMPF?
Los precios de IMMPF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre IMMPF?
La cobertura de analistas para IMMPF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en IMMPF?
Las categorías de riesgo para IMMPF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Failure of Lupuzor Phase III clinical trial.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de IMMPF?
La relación P/E para IMMPF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está IMMPF sobrevalorada o infravalorada?
Determinar si ImmuPharma plc (IMMPF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de IMMPF?
ImmuPharma plc (IMMPF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide further insights.